The Next Phase In Oncology: FDA’s Pazdur On “Breakthrough” Drug Development
This article was originally published in RPM Report
Executive Summary
At a small press briefing on personalized medicine, FDA’s top cancer drug reviewer paints a picture of the next phase in cancer drug development.